180 Degree Capital
VC Fund
New York, United States
180 Degree Capital is a VC fund in New York focused on Manufacturing and Biotechnology. With some 25 tiny technology companies in our portfolio, Harris & Harris Group, Inc.®, is one of the most active nanotechnology investors in the world. They have funded companies developing nanoscale-enabled solutions in solid state lighting, emerging memory devices, printable electronics, material science discovery and mass-manufacturing,organic-inorganic hybrids, next-generation semiconductor devices and equipment, thermoelectric, photovoltaic and battery technologies, as well as in various life-science applications of nano-structured materials.They participate in venture capital syndicates in most of their investments, alongside top-tier venture capital firms as well as strategic (corporate) investors. Increasingly, Harris & Harris Group is a lead investor. They believe in the classical early stage venture capital model and disciplines and that most technology-based start-ups can use all the help they can get from the diversified experiences, Rolodexes®, complimentary business networks, technical expertise, up-to-date customer connections and financial resources that a syndicate of professional venture capital investors can provide.Harris & Harris Group will invest at any stage prior to a company's initial public offering, and they will invest anywhere in the United States. Occasionally, they have also made private investments in publicly held companies (so-called "PIPE" investments). They have invested outside the United States, but rarely. Their current portfolio companies are distributed all across the country, plus one in Canada.Harris & Harris Group is looking for scientific, technological, business and execution excellence. They are attracted to markets of significant size and back passionate entrepreneurs who want to change the world with their tiny technology-enabled products.Proprietary, well-protected and highly differentiated technology is a prerequisite. But above all, they are eager to invest in companies with market-centric strategies that seek to define and dominate large product categories.
- Total investments:
- 54
- Last investment:
- Lead investor:
- 4%
Last updated:
For AI agents: llms.txt
Industries 180 Degree Capital invests in
Stages 180 Degree Capital invests in
Countries 180 Degree Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Manufacturing 16 (30%)
- Biotechnology 12 (22%)
- Health Care 10 (19%)
- Semiconductor 9 (17%)
- Electronics 6 (11%)
Stage
- Series B 13 (24%)
- Funding Round 11 (20%)
- Series A 9 (17%)
- Series C 9 (17%)
- Series D 5 (9%)
Country
- United States 32 (59%)
- Canada 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Blake Stevens
Associate
|
Associate | Total investments: 3 | Find email | |
|
Charles E. Harris
Chairman and CEO
|
Chairman and CEO | Total investments: 3 | Find email | |
Daniel Wolfe
Portfolio Manager, President & CFO
|
Portfolio Manager, President & CFO | Total investments: 1 | Find email | |
|
CARMEN DEFOREST
Executive Assistant
|
Executive Assistant | Total investments: 0 | Find email | |
Douglas W. Jamison
Founder, Chairman and CEO
|
Founder, Chairman and CEO | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EchoPixel
|
EchoPixel, Inc. develops medical imaging devices. The company develops a non-invasive colon cancer screening solution that enables doctors and radiologists to use computed tomography (CT) images of a patient’s abdomen and display a 3D model of a patient’s colon. With this tool, any medical professional can examine the entire colon by using anavigate and detect approach to identify most polyps or other abnormalities, the cause of cancer. The company was incorporated in 2012 and is based in San Jose, California. | Series A / Oct 19, 2017 | |
NGX Bio
|
NGX Bio is an online marketplace platform for online DNA sequencing services. They make sequencing simple by connecting their customers to world-class genomic resources helping researchers complete sequencing projects in a single transaction. It streamlines the projects and makes them cost-effective by sourcing the best providers with availablecapacity.NGX Bio offers design and planning, sample preparation, sequencing facilities, and data analysis services. The company also operates an online project management tool that helps in sample tracking by using barcoded tubes and plates. NGX Bio serves customers worldwide. | $3M / Aug 15, 2017 | |
ORIG3N
|
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts. | $20M / Jun 27, 2017 | |
Lodo Therapeutics
|
Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some ofthe greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park. | $17M / Series A / Jan 11, 2016 | |
|
ORIG3N
|
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts. | $12.5M / Series A / Dec 12, 2015 | |
|
ORIG3N
|
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts. | $3.1M / Feb 05, 2015 | |
HZO
|
HZO delivers customized protective nano and conformal coatings that safeguard electronics from the most demanding environments. It provides water protection solutions for electronics manufacturers by introducing a durable film to components during assembly. The company specializes in the fields of nanotechnology, waterproofing, electronics,nano-coating, full-submersion.It was founded in 2011 and headquartered in Morrisville, North Carolina. | $20M / Series B / Jul 01, 2014 | |
Nantero
|
Nantero is a next-generation memory technology that, packs massive amounts of storage and is nonvolatile. Its main focus is the commercial introduction of NRAM – a high-density high-speed nonvolatile random access storage device. The applications for the nonvolatile RAM Nantero is developing include smartphones, tablets, enterprise systems,notebook and desktop computers, as well as applications in the automotive and industrial arena. NRAM can be manufactured for both standalone and embedded memory applications. Nantero is also working with licensees on the development of additional applications of Nantero’s core nanotube-based technology. | $15M / Series D / Nov 28, 2012 | |
Kovio
|
Kovio Inc., a privately held Silicon Valley company, is developing a new category of semiconductor products using printed silicon electronics and thin film technology. This new manufacturing technology combines the low cost of graphics printing with the power and functionality of silicon-based semiconductors. The company was founded in the MITMedia Laboratory. | $7M / Jul 01, 2012 | |
OpGen
|
Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with morerapid and actionable information about life threatening infections to improve patient outcomes. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications. | $17M / Series C / Mar 07, 2012 | |
| See all 54 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does 180 Degree Capital invest in?
180 Degree Capital invests primarily in Manufacturing, Biotechnology and Health Care startups, most often at Series B and Funding Round stage. Most of the 54 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact 180 Degree Capital?
Public channels for 180 Degree Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at 180 Degree Capital?
The team at 180 Degree Capital includes Blake Stevens (Associate), Charles E. Harris (Chairman and CEO) and Daniel Wolfe (Portfolio Manager, President & CFO), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
